MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors

Paolo Luraghi, Gigliola Reato, Elia Cipriano, Francesco Sassi, Francesca Orzan, Viola Bigatto, Francesca De Bacco, Elena Menietti, May Han, William M. Rideout, Timothy Perera, Andrea Bertotti, Livio Trusolino, Paolo M. Comoglio, Carla Boccaccio

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be supported by a subpopulation of stem-like cells termed colon cancer initiating cell (CCIC), which may also confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully characterized. To explore this question, we systematically generated CCICs through spheroid cultures of patient-derived xenografts of metastatic colorectal cancer. These cultures, termed "xenospheres," were capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET inhibition, which sensitized the response to EGFR therapy. By showing that RASwt CCICs rely on both EGFR and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two pathways in the clinical setting.

Original languageEnglish
Pages (from-to)1857-1869
Number of pages13
JournalCancer Research
Volume74
Issue number6
DOIs
Publication statusPublished - Mar 15 2014

Fingerprint

Neoplastic Stem Cells
Heterografts
Colonic Neoplasms
Colorectal Neoplasms
Proto-Oncogene Proteins c-met
Critical Pathways
Therapeutics
Epidermal Growth Factor Receptor
Genes
Neoplasms
Stem Cells
Cell Proliferation
Cytokines
Ligands
Survival
Antibodies
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. / Luraghi, Paolo; Reato, Gigliola; Cipriano, Elia; Sassi, Francesco; Orzan, Francesca; Bigatto, Viola; De Bacco, Francesca; Menietti, Elena; Han, May; Rideout, William M.; Perera, Timothy; Bertotti, Andrea; Trusolino, Livio; Comoglio, Paolo M.; Boccaccio, Carla.

In: Cancer Research, Vol. 74, No. 6, 15.03.2014, p. 1857-1869.

Research output: Contribution to journalArticle

Luraghi, P, Reato, G, Cipriano, E, Sassi, F, Orzan, F, Bigatto, V, De Bacco, F, Menietti, E, Han, M, Rideout, WM, Perera, T, Bertotti, A, Trusolino, L, Comoglio, PM & Boccaccio, C 2014, 'MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors', Cancer Research, vol. 74, no. 6, pp. 1857-1869. https://doi.org/10.1158/0008-5472.CAN-13-2340-T
Luraghi, Paolo ; Reato, Gigliola ; Cipriano, Elia ; Sassi, Francesco ; Orzan, Francesca ; Bigatto, Viola ; De Bacco, Francesca ; Menietti, Elena ; Han, May ; Rideout, William M. ; Perera, Timothy ; Bertotti, Andrea ; Trusolino, Livio ; Comoglio, Paolo M. ; Boccaccio, Carla. / MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. In: Cancer Research. 2014 ; Vol. 74, No. 6. pp. 1857-1869.
@article{54e789b5854c44e99ab7554ec59084ce,
title = "MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors",
abstract = "Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be supported by a subpopulation of stem-like cells termed colon cancer initiating cell (CCIC), which may also confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully characterized. To explore this question, we systematically generated CCICs through spheroid cultures of patient-derived xenografts of metastatic colorectal cancer. These cultures, termed {"}xenospheres,{"} were capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET inhibition, which sensitized the response to EGFR therapy. By showing that RASwt CCICs rely on both EGFR and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two pathways in the clinical setting.",
author = "Paolo Luraghi and Gigliola Reato and Elia Cipriano and Francesco Sassi and Francesca Orzan and Viola Bigatto and {De Bacco}, Francesca and Elena Menietti and May Han and Rideout, {William M.} and Timothy Perera and Andrea Bertotti and Livio Trusolino and Comoglio, {Paolo M.} and Carla Boccaccio",
year = "2014",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-13-2340-T",
language = "English",
volume = "74",
pages = "1857--1869",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors

AU - Luraghi, Paolo

AU - Reato, Gigliola

AU - Cipriano, Elia

AU - Sassi, Francesco

AU - Orzan, Francesca

AU - Bigatto, Viola

AU - De Bacco, Francesca

AU - Menietti, Elena

AU - Han, May

AU - Rideout, William M.

AU - Perera, Timothy

AU - Bertotti, Andrea

AU - Trusolino, Livio

AU - Comoglio, Paolo M.

AU - Boccaccio, Carla

PY - 2014/3/15

Y1 - 2014/3/15

N2 - Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be supported by a subpopulation of stem-like cells termed colon cancer initiating cell (CCIC), which may also confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully characterized. To explore this question, we systematically generated CCICs through spheroid cultures of patient-derived xenografts of metastatic colorectal cancer. These cultures, termed "xenospheres," were capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET inhibition, which sensitized the response to EGFR therapy. By showing that RASwt CCICs rely on both EGFR and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two pathways in the clinical setting.

AB - Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be supported by a subpopulation of stem-like cells termed colon cancer initiating cell (CCIC), which may also confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully characterized. To explore this question, we systematically generated CCICs through spheroid cultures of patient-derived xenografts of metastatic colorectal cancer. These cultures, termed "xenospheres," were capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET inhibition, which sensitized the response to EGFR therapy. By showing that RASwt CCICs rely on both EGFR and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two pathways in the clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84896532797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896532797&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-2340-T

DO - 10.1158/0008-5472.CAN-13-2340-T

M3 - Article

VL - 74

SP - 1857

EP - 1869

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -